Alzheimer's Disease Cooperative Study (ADCS)
阿尔茨海默病合作研究(ADCS)
基本信息
- 批准号:8545378
- 负责人:
- 金额:$ 608.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-07-01 至 2012-11-30
- 项目状态:已结题
- 来源:
- 关键词:Advanced Glycosylation End ProductsAffectAffectiveAgeAlzheimer&aposs DiseaseAmino AcidsAmyloidAntibodiesAntioxidantsBindingBiologicalBiological MarkersBiotechnologyClinicalClinical InvestigatorClinical TrialsCognitionCognitiveComorbidityComputersDataData CollectionDepositionDevice or Instrument DevelopmentDocosahexaenoic AcidsElderlyFundingFutureHealthHome environmentIndividualLaboratoriesMailsMeasurableMeasuresMethodsMinorityMinority GroupsNeuroprotective AgentsOmega-3 Fatty AcidsPassive ImmunizationPatientsPeptidesPharmaceutical PreparationsPhasePhosphorylationPlantsPrimary PreventionProteinsQuality of lifeQuestionnairesRecruitment ActivityResearch PersonnelResourcesResveratrolSenile PlaquesSignal TransductionSimulateSiteSymptomsTechnologyTelephoneTestingTrainingUnited StatesVoiceage relatedbasecohortcomputerizedcooperative studycostdesignefficacy trialimprovedinnovationinstrumentinterestmembernovelnovel strategiespolyphenolreceptorred wineresponsesuccessful interventiontau Proteins
项目摘要
DESCRIPTION (provided by applicant): This proposal is for a 5 year renewal (years 16-20) of the Alzheimer's Disease Cooperative Study (ADCS). This consortium of 34 members' sites and 46-56 participating sites is proposing both continued instrument development as well as new clinical drug studies. Instrument development will focus on innovative methods of home based assessments for a broad cohort of normal elderly(over age 75) who may have significant co-morbidities in a simulated primary prevention trial employing mail-in questionnaires, automated telephone technology and computerized data collection to assess cognitive, functional, affective, global, quality of life, and resource use measures in the home environment.
The ADCS has assembled its most exciting portfolio of clinical drug trials by seeking new and innovative compounds form the biotechnology sector, individual investigator laboratories as well as from its own members. We are proposing 3 phase 3 efficacy trials of agents designed to slow progression of AD: (1) TTP488, a small novel molecule that binds to and inhibits the receptor for advanced glycation end products (RAGE) which blocks deposition of A?, (2) NAP, a novel eight amino acid peptide derived from the sequence of activity dependent neuroprotective protein(ADNP), the most potent neuroprotectant molecule currently known and (3) docosahexaenoic acid (DHA), an omega-3 fatty acid with anti-amyloid, anti-oxidant, and neuroprotectant effects. Two biomarker trials are proposed to determine if molecules of interest can produce a measurable biological signal for consideration for future efficacy trials: (1) Li, a molecule that blocks phosphorylation of tau protein and (2) resveratrol, a polyphenol derived from plants and red wine that retards the age-dependent deposition and accumulation of CNS A? and amyloid plaques. Finally, we will test the ability of passive immunization using Mg which contains natural anti-amyloid antibodies and has been demonstrated to improve cognition in early clinical trials in AD.
Our existing minority recruitment core is being expanded into a general recruitment core focused on maximizing the recruitment of minorities and other subjects into our clinical trials.
描述(由申请人提供):本提案为阿尔茨海默病合作研究(ADCS)的5年续期(16-20年)。这个由34个成员单位和46-56个参与单位组成的联合体正在提议继续进行仪器开发和新的临床药物研究。仪器开发将侧重于创新的家庭评估方法,针对在模拟一级预防试验中可能有显著合并症的正常老年人(75岁以上),采用邮寄问卷、自动电话技术和计算机数据收集来评估家庭环境中的认知、功能、情感、全球、生活质量和资源使用措施。
项目成果
期刊论文数量(79)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Measuring behavior, mood, and psychiatric symptoms in Alzheimer disease.
测量阿尔茨海默病的行为、情绪和精神症状。
- DOI:
- 发表时间:1997
- 期刊:
- 影响因子:0
- 作者:Teri,L;Logsdon,R;Yesavage,J
- 通讯作者:Yesavage,J
Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study.
司来吉兰和α-生育酚治疗阿尔茨海默病的多中心研究的基本原理和设计,采用新颖的临床结果。
- DOI:10.1097/00002093-199601030-00004
- 发表时间:1996
- 期刊:
- 影响因子:0
- 作者:Sano,M;Ernesto,C;Klauber,MR;Schafer,K;Woodbury,P;Thomas,R;Grundman,M;Growdon,J;Thal,LJ
- 通讯作者:Thal,LJ
Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.
- DOI:10.14283/jpad.2015.62
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Aisen PS
- 通讯作者:Aisen PS
Neurodegenerative disorders with diffuse cortical Lewy bodies.
弥漫性皮质路易体神经退行性疾病。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Fleisher,AdamS;Olichney,JohnM
- 通讯作者:Olichney,JohnM
Assessment and management of behavioral disturbances in Alzheimer disease.
阿尔茨海默病行为障碍的评估和管理。
- DOI:10.1007/s12019-000-0005-x
- 发表时间:2000
- 期刊:
- 影响因子:0
- 作者:Teri,L;Logsdon,RG
- 通讯作者:Logsdon,RG
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul S. Aisen其他文献
Poster Number: EI 19 - Association of Subjective Cognitive Complaints and Objective Cognitive Impairment in Late Life Depression
- DOI:
10.1016/j.jagp.2018.01.110 - 发表时间:
2018-03-01 - 期刊:
- 影响因子:
- 作者:
Ruth Morin;David D. Bickford;Yiu Ho Au;Kelly B. Scherer;Daniel C. Catalinotto;Philip Insel;Duygu Tosun;Michelle Zmuda;Arthur W. Toga;Paul S. Aisen;Rema Raman;Andrew Saykin;Michael Weiner;Meryl A. Butters;Craig Nelson;Scott Mackin - 通讯作者:
Scott Mackin
NAP ameliorates Alzheimer’s pathology in ad model mouse
- DOI:
10.1016/j.npep.2006.09.022 - 发表时间:
2006-12-01 - 期刊:
- 影响因子:
- 作者:
Y. Matsuoka;Illana Gozes;Paul S. Aisen - 通讯作者:
Paul S. Aisen
The Development of Anti-Amyloid Therapy for Alzheimer’s Disease
- DOI:
10.2165/00023210-200519120-00002 - 发表时间:
2005-01-01 - 期刊:
- 影响因子:7.400
- 作者:
Paul S. Aisen - 通讯作者:
Paul S. Aisen
Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review
- DOI:
10.1016/j.arr.2022.101777 - 发表时间:
2022-12-01 - 期刊:
- 影响因子:12.400
- 作者:
Nicola Coley;Caroline Giulioli;Paul S. Aisen;Bruno Vellas;Sandrine Andrieu - 通讯作者:
Sandrine Andrieu
Paul S. Aisen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul S. Aisen', 18)}}的其他基金
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
无症状阿尔茨海默病 (A4) 开放标签扩展研究中的抗淀粉样蛋白治疗
- 批准号:
10554282 - 财政年份:2019
- 资助金额:
$ 608.15万 - 项目类别:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
无症状阿尔茨海默病 (A4) 开放标签扩展研究中的抗淀粉样蛋白治疗
- 批准号:
10358480 - 财政年份:2019
- 资助金额:
$ 608.15万 - 项目类别:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
无症状阿尔茨海默病 (A4) 开放标签扩展研究中的抗淀粉样蛋白治疗
- 批准号:
9930020 - 财政年份:2019
- 资助金额:
$ 608.15万 - 项目类别:
Combination anti-amyloid therapy for preclinical Alzheimer's disease
临床前阿尔茨海默病的抗淀粉样蛋白联合治疗
- 批准号:
9786200 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Combination anti-amyloid therapy for preclinical Alzheimer's disease
临床前阿尔茨海默病的抗淀粉样蛋白联合治疗
- 批准号:
10452475 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Combination anti-amyloid therapy for preclinical Alzheimer's disease
临床前阿尔茨海默病的抗淀粉样蛋白联合治疗
- 批准号:
10666411 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Alzheimer's Clinical Trials Consortium (ACTC)
阿尔茨海默病临床试验联盟 (ACTC)
- 批准号:
10435786 - 财政年份:2017
- 资助金额:
$ 608.15万 - 项目类别:
Alzheimers Clinical Trials Consortium (ACTC)
阿尔茨海默病临床试验联盟 (ACTC)
- 批准号:
9753042 - 财政年份:2017
- 资助金额:
$ 608.15万 - 项目类别:
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
临床前/前驱阿尔茨海默病的试验就绪队列
- 批准号:
9885998 - 财政年份:2017
- 资助金额:
$ 608.15万 - 项目类别:
相似海外基金
Affective Virality on Social Media: The Role of Culture and Ideal Affect
社交媒体上的情感病毒传播:文化和理想情感的作用
- 批准号:
2214203 - 财政年份:2022
- 资助金额:
$ 608.15万 - 项目类别:
Standard Grant
'Essaying Affect: the contemporary essay as a place of affective possibility'
“散文情感:当代散文作为情感可能性的场所”
- 批准号:
2438692 - 财政年份:2020
- 资助金额:
$ 608.15万 - 项目类别:
Studentship
Influence of Physical Activity on Daily Positive Affect & Affective Neural Activity in Preschoolers
体力活动对日常积极影响的影响
- 批准号:
10231121 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Influence of Physical Activity on Daily Positive Affect & Affective Neural Activity in Preschoolers
体力活动对日常积极影响的影响
- 批准号:
10475608 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Influence of Physical Activity on Daily Positive Affect & Affective Neural Activity in Preschoolers
体力活动对日常积极影响的影响
- 批准号:
10474838 - 财政年份:2018
- 资助金额:
$ 608.15万 - 项目类别:
Affect- and Psychotechnolog Studies. Emergent Technologies of Affective and Emotional (Self-)Control
影响和心理技术研究。
- 批准号:
279966032 - 财政年份:2015
- 资助金额:
$ 608.15万 - 项目类别:
Scientific Networks
Does minute listeners' head movement affect affective aspects of human spatial hearing perception?
听众的微小头部运动是否会影响人类空间听觉感知的情感方面?
- 批准号:
26540093 - 财政年份:2014
- 资助金额:
$ 608.15万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
RI: Small: An Affect-Adaptive Spoken Dialogue System that Responds Based on User Model and Multiple Affective States
RI:Small:基于用户模型和多种情感状态进行响应的情感自适应口语对话系统
- 批准号:
0914615 - 财政年份:2009
- 资助金额:
$ 608.15万 - 项目类别:
Standard Grant
Affective Rendering ? Toward the Realization of Affect Adapted Image Synthesis
情感渲染?
- 批准号:
21300033 - 财政年份:2009
- 资助金额:
$ 608.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A Study by Means of Analysis of Structure of Covariunce, on Factors which Affect Japanese Language Acquisition and Mother Tongue Maintenance of Children from Overseas-an Integral Study of Cognitive Linguistic / Affective / Socio Cultural Factors-
协方差结构分析影响海外儿童日语习得和母语维持的因素研究-认知语言/情感/社会文化因素的综合研究-
- 批准号:
11480051 - 财政年份:1999
- 资助金额:
$ 608.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)